Topiramate Tablet
Product Images NDC 80425-0373

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Topiramate (NDC 80425-0373). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Advanced Rx Pharmacy Of Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Topiramate 100mg #30 (Topiramate 100mg 80425 0373 01)

Topiramate 100 mg tablet packaging label by Advanced Rx Pharmacy of Tennessee, LLC. The label includes storage instructions (20°-25°C), a comparison to Topamax, prescription-only status, and a count of 30 tablets. It displays product NDC 80425-0373 and an expiration date of 6/30/2025.*

FDA Label Image

Topiramate 100 mg #60 (Topiramate 100mg 80425 0373 02)

Topiramate 100 mg tablet packaging label from Advanced Rx Pharmacy of Tennessee, LLC. The label includes storage instructions (store at 20-25°C/68-77°F), comparison to Topamax, and identification details including NDC 80425-0373, lot number, and expiration date of 6/30/2025. The label notes the drug is provided by CIPLA USA, Inc.*

FDA Label Image

Topiramate 100 mg #90 (Topiramate 100mg 80425 0373 03)

Topiramate 100 mg tablet packaging label from Advanced Rx Pharmacy of Tennessee, LLC. The label includes storage instructions (20-25°C), a comparison to Topamax, NDC number 80425-0373-03, and an expiration date of 6/30/2025. Package count is 90 tablets, with CIPLA USA, Inc. as a noted manufacturer.*

FDA Label Image

Topi (Ccb7a1e4 A3a1 4a0e 8eb0 8086f53e314b 01)

Chemical structure of Topiramate, showing the molecular arrangement with multiple rings, oxygen atoms, methyl groups, and a sulfonamide functional group.*

FDA Label Image

Topi (Ccb7a1e4 A3a1 4a0e 8eb0 8086f53e314b 02)

A line graph displaying cumulative rates for time to first seizure over 500 days for two daily doses of Topiramate: 50 mg/day and 400 mg/day. The solid line represents 50 mg/day (N=234), and the dotted line represents 400 mg/day (N=236), showing higher cumulative rates for the lower dose group. The graph includes a p-value of 0.0002.*

FDA Label Image

Figure 2: Reduction In 4-week Migraine Headache Frequency(studies 10 And 11 For Adults And Adolescents) (Ccb7a1e4 A3a1 4a0e 8eb0 8086f53e314b 03)

A bar chart comparing the change from baseline to double-blind phase in average weekly migraine days per 4-week period for placebo and Topamax (topiramate) at 50 mg/day, 100 mg/day, and 200 mg/day doses. Two studies (Study 10 and Study 11) are represented with different bar patterns, showing dose-related decreases in migraine days with statistical significance indicated.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.